This article is more than 5 years old. Information may no longer be current.

Aerie reports quarterly net loss of $13.1 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals reported a net loss of $13.1 million, or $0.54 per share, in the third quarter, compared with a loss of $10.9 million, or $10.81 per share, in the third quarter 2013 when the company was privately held, according to a press release.

The net loss was attributed to higher operating expenses related to more clinical and nonclinical activities for Rhopressa, more nonclinical activities for Roclatan and an increase in supporting growth in operations.

Aerie had $171.1 million in total current assets as of Sept. 30, compared with $70.3 million as of Dec. 31, 2013.